Health Care [ 7/12 ] | Biotechnology [ 39/74 ]
NYSE MKT | Common Stock
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.
The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers.
It also has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder.
The company is headquartered in Toronto, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 11, 25 | -0.53 Decreased by -488.89% | -1.57 Increased by +66.19% |
| Nov 13, 24 | -2.86 Decreased by -5.62 K% | -0.91 Decreased by -215.15% |
| Aug 8, 24 | -0.02 Increased by +71.43% | -0.02 |
| Jun 26, 24 | -0.02 Increased by +71.43% | -0.03 Increased by +39.94% |
| Feb 14, 24 | -0.09 Decreased by -50.00% | -0.04 Decreased by -125.00% |
| Nov 13, 23 | -0.05 Increased by +16.67% | -0.05 |
| Aug 14, 23 | -0.07 Increased by 0.00% | -0.06 Decreased by -16.67% |
| Jun 27, 23 | -0.07 Increased by +30.00% | -0.06 Decreased by -16.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -57.19 M Decreased by -88.57% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -14.82 M Decreased by -19.79% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -21.35 M Decreased by -55.58% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -21.35 M Decreased by -98.72% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -30.33 M Decreased by -204.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -12.38 M Increased by +5.21% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -13.72 M Increased by +24.19% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -10.74 M Increased by +37.58% | Decreased by N/A% Decreased by N/A% |